Advancing therapy with iGlarLixi safe and effective for diabetes treatment irrespective of SGLT2 inhibitors use: Study
A patient-level pooled analysis of three randomized clinical trials (RCTs) revealed improvement in glycemic status without increased risk of hypoglycemia with iGlarLixi, regardless of concomitant use of SGLT2 inhibitors. The study was published online in Diabetes Research and Clinical Practice on March 4, 2024. The study showed similar clinically meaningful improvements in HbA1c in both […]